Stocks Health care PBM

NASDAQ · Health care

Psyence Biomedical Ltd. (PBM)

In fiscal 2025 capital spending exceeded operating cash flow by $3.7M. At March 31, 2025 it held $6.1M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on June 22, 2026.

What Psyence Biomedical Ltd. does

Psyence Biomedical Ltd. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PBM.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What Psyence Biomedical Ltd. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. September 23, 2026
   Foreign issuer update 6-K
2. September 14, 2026
   Foreign issuer update 6-K
3. August 26, 2026
   Employee stock plan registration S-8
4. August 26, 2026
   Form F-3 filing F-3
5. August 6, 2026
   Foreign issuer update 6-K
6. June 22, 2026
   Annual report (foreign issuer) 20-F · period to March 31, 2026
7. June 10, 2026
   Passive stake changed SCHEDULE 13G/A
8. June 5, 2026
   Foreign issuer update 6-K
9. June 3, 2026
   Activist stake (5% or more) SCHEDULE 13D
10. April 23, 2026
    Foreign issuer update 6-K

Who owns PBM

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Latest filings below 5%: Weiner Jeffrey David 2.61% (June 10, 2026); KAOS Capital Ltd. 4.91% (January 13, 2026); Harraden Circle Investments, LLC 0% (May 15, 2025); Hudson Bay Capital Management LP 4.99% (May 14, 2025); Psyence Group Inc. 0% (May 12, 2025).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

We have not read this company's Form 4 filings yet.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about PBM

What does Psyence Biomedical Ltd. do?

Psyence Biomedical Ltd. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PBM.

Is Psyence Biomedical Ltd. profitable?

Yes. In fiscal 2025 it reported net income of $1M.

When did Psyence Biomedical Ltd. last report?

Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on June 22, 2026. It covers the period to March 31, 2026. Its newest filing of any kind is the foreign issuer update from September 23, 2026.

Similar companies

Compare PBM with

Compare PBM with any company

Follow PBM

Get an email when Psyence Biomedical Ltd. files with the SEC: results, executive changes, material agreements and annual reports.

Follow PBM: get an email when it files

Where the numbers come from

Financial figures are the values Psyence Biomedical Ltd. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.